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Case Description:  
 
A 77 year-old right-handed functionally-independent man presented after waking with a 
right-sided frontal headache, associated with three episodes of vomiting. His headache 
progressed over the following twenty minutes, prompting presentation to the Emergency 
Department. He reported an unsteady gait, but no focal weakness or sensory disturbance. He 
was known to be in atrial fibrillation (AF), for which he was anticoagulated with warfarin. 
His other comorbidities included a previous pulmonary embolus, hypertension, and benign 
prostatic hypertrophy. 
 
On examination, there was no focal neurological deficit and his Glasgow Coma Scale was 15. 
In view of his severe headache whilst therapeutically anticoagulated, he was investigated 
with an urgent computed tomography (CT) scan of his head. This demonstrated a 58 by 37 
mm right temporal lobe hemorrhage (figure 1). His international normalized ratio (INR) on 
admission was 2.13, which was corrected with vitamin K and prothrombin complex. The 
hemorrhage was managed conservatively with blood pressure control, initially requiring a 
labetalol infusion followed by oral lisinopril and doxazosin. 
 
He remained neurologically stable throughout his admission. He was discharged 14 days later 
with a minor deficit in short-term memory but no other focal neurological deficit. His 
modified Rankin score was one. In view of the acute hemorrhage, anticoagulation was 
withheld as further hemorrhagic risk was deemed to outweigh antithrombotic benefit. 
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Magnetic resonance imaging (MRI) was performed one month after discharge and 
demonstrated evolution of the hematoma (figures 2a and 2b). Gradient echo images also 
demonstrated a small right parietal lobe hemorrhage (figure 2c). These findings were 
suggestive of cerebral amyloid angiopathy (CAA) as the etiology of his presenting right 
temporal lobe hemorrhage.  
 
In view of the findings suggestive of CAA, it was felt that the risks of recurrent bleeding with 
long-term anticoagulation outweighed the benefits of stroke risk-reduction from AF-related 
thromboembolism. He was therefore referred to the regional cardiothoracic centre for 
consideration for a left atrial appendage closure. 
 
Discussion: 
 
This case highlights the management challenge in balancing the ischemic stroke risk from AF 
against the recurrent hemorrhagic stroke risk from CAA following an intracerebral 
hemorrhage. The prevalence of CAA increases with age, and was identified in 57% of 
patients aged over 59 years in one autopsy study.1 Consequently, a large cohort in the general 
population will have concomitant AF and CAA, though the latter may be undetected unless 
gradient echo MRI is performed. CAA is a common cause of intracerebral hemorrhage in 
patients over 60 years of age, and it has been reported to underly 12-20% of intracerebral 
hemorrhages in two large retrospective studies.2,3  In contrast to intracerebral hemorrhages of 
hypertensive etiology, which tend to occur in subcortical areas, hemorrhages secondary to 
CAA tend to occur in the cerebral cortex and display a lobar pattern.4 Histopathological 
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confirmation is required to make a definitive diagnosis of CAA, but the presence of lobar 
intracerebral hemorrhage on non-contrast CT, or multiple cortical microhemorrhages on 
gradient echo MRI in a patient older than 55 years of age, is highly suggestive for CAA.4 The 
differential diagnosis of CAA can be further supported by the modified Boston criteria, which 
incorporates criteria including age, neuro-imaging findings, and post-mortem histology to 
offer a high sensitivity and specificity in the diagnosis of CAA. 
 
The risk of cardioembolic stroke from AF is well-recognized and is influenced by the 
presence of comorbidities such as congestive cardiac failure, diabetes mellitus, previous 
stroke, and hypertension. The attributable risk of stroke for individuals with AF increases 
with age, rising from 1.5% for patients in their sixth decade, to 23.5% in the ninth decade.5 In 
the absence of contraindications, anticoagulation with warfarin or a direct oral anticoagulant 
(either a direct thrombin inhibitor or a factor Xa inhibitor) is used to reduce the risk of 
cardioembolic ischemic stroke secondary to AF, and is recommended in men with a 
CHA2DS2-VASc score >1 and in women with a CHA2DS2-VASc score of >2.6  
 
In patients who have had an intracerebral hemorrhage with co-existing AF and CAA, the risk 
of ischemic stroke without anticoagulation must be carefully considered against the risks of 
recurrent intracerebral hemorrhage exacerbated by anticoagulation. A decision-analysis 
model for the use of warfarin in AF in the setting of a previous intracerebral hemorrhage 
suggests that the risks associated with warfarin outweigh the benefits, particularly when 
comparing lobar to deep intracerebral hemorrhage; the withholding of warfarin resulting in an 
increase in quality-adjusted life expectancy by 1.9 and 0.3 quality-adjusted life years 
respectively.7 The estimated risk of recurrent intracerebral hemorrhage in CAA varies, with a 
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review by Poon et al. estimating that the risk of recurrent hemorrhage for lobar hemorrhages 
after 1 year to be between 2.5-28.2%, compared to a lower risk of 1.3-10.6% in non-lobar 
hemorrhage.8 There are currently no guidelines on anticoagulant use in the setting of AF 
following intracerebral hermorrhage secondary to concomitant CAA. Consequently, 
management of such patients remains a challenge. The HAS-BLED score is not validated for 
use in CAA so risk stratification must be based on the aforementioned recurrence rates 
balanced against the CHA2DS2-VASc score. In the case of our patient, his CHA2DS2-VASc 
score was 5, giving him an adjusted ischemic stroke risk of 6.7% per annum, whilst the 
pooled results from Poon et al. would suggest that the rate of lobar hemorrhage reccurrence 
for those not taking anticoagulation exceeds this ischemic stroke risk even before the 
additional hemorrhagic risk from anticoagulation is considered.8 
 
The recurrence rate of intracerebral hemorrhage in CAA secondary to antiplatelet use is also 
unclear, largely due to randomized clinical trials often excluding patients with previous 
intracerebral hemorrhage in trials of antithrombotics. Longitudinal observational cohort 
studies (typically single centre studies of small numbers) have shown conflicting results for 
recurrence of lobar hemorrhage for individuals taking antiplatelet medication. This, coupled 
with the lack of efficacy for aspirin preventing stroke in patients with AF, casts uncertainty 
on the role of antithrombotic agents in concomitant AF and CAA.6 Further research and 
meta-analysis into this area is required, and a Cochrane Library review is currently in 
progress.  
 
In view of the inherent bleeding risk associated with anticoagulation in AF, there has been 
much interest in non-pharmacological methods for reducing thromboembolic stroke risk. The 
	   5	  
left atrial appendage has been shown to be the source of thromboemboli in 90% of patients 
with non-valvular AF, and excluding the left atrial appendage from the systemic circulation 
has been investigated to reduce the risk of cardio-embolism.9 Percuteneously implanted 
closure devices can be used to achieve this, potentially offering an avenue to reduce the risk 
of thromboembolism secondary to AF, whilst avoiding the risks of anticoagulation-associated 
intracerebral hemorrhage. Left atrial appendage closure was shown to be at least non-inferior 
to anticoagulation with a relative risk of stroke, cardiovascular death, and systemic 
embolization of 0.62 (95% CI 0.35-1.25) for the intervention versus anticoagulation group.9 It 
should be noted that in this study, patients remained on warfarin until closure of the left atrial 
appendage was confirmed on trans-oesophageal echocardiogram, and the safety in patients in 
whom anticoagulation is contraindicated is yet to be fully determined. More recently, the 
procedure itself has been shown to be feasible and safe in individuals with concomitant AF 
and previous intracerebral hemorrage who received peri-procedural heparin, though such 
studies did not discrimate hemorrhages by etiology.10 A further small study has suggested 
that left atrial appendage closure can be performed safely and effectively with antithrombotic 
agent cover rather than anticoagulation but the safety of antithrombotic agents in CAA also 
remains uncertain.11 Superiority of either left atrial appendage closure or longterm 
anticoagulation requires further study, though is difficult to demonstrate due to low event 
rates in each treatment arm. Nevertheless, as the facility for left atrial appendage closure 
becomes increasingly available, it may provide a safe alternative strategy for stroke risk-
reduction for patients with AF complicated with other bleeding risks. 
 
Balancing the risk of ischemic stroke and hemorrhagic stroke in patients with co-existing AF 
and CAA remains a challenging area, and requires careful consideration on a case-by-case 
basis. Guideline development requires a greater understanding of the safety of anticoagulant 
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and antithrombotic drugs in these patients, and of the safety of left atrial appendage exclusion 
procedures without the concomitant use of these agents. Future research and clinical 
management must consider the underlying etiology of the hemorrhage for risk prediction to 
guide treatment. 
 
Take-Home Points 
 
• Cerebral amyloid angiopathy is difficult to diagnose definitively, but may be 
suspected based on imaging findings of lobar intracerebral hemorrhage on non-
contrast CT or microhemorrhages on gradient echo MRI. 
 
• There is a high risk of recurrent hemorrhage in patients with intracerebral hemorrhage 
secondary to cerebral amyloid angiopathy, above that expected with non-lobar 
hemorrhages. 
 
• Anticoagulant and antithrombotic agents should be avoided in the setting of cerebral 
amyloid angiopathy unless the risk of ischemic stroke outweighs the high risk of 
hemorrhagic stroke. 
 
• Left atrial appendage closure may provide a safe alternative for reducing the risk of 
ischemic stroke in atrial fibrillation for individuals where anticoagulation is 
contraindicated. 
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Figure 1. Non-contrast axial CT head showing a right temporal lobe intracerebral 
hemorrhage (maximum diameter 58 x 37 mm) and associated mass effect with sulcal 
effacement. 
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Figure 2. MRI head performed one month following intracerebral hemorrhage. A, Gradient 
echo and B, T2-weighted MRI showing evolution of the hemorrhage, with low intensity 
peripherally, indicating hemosiderin formation. C, Gradient echo demonstrating an additional 
8mm focal right parietal hemorrhage (arrow). 
 
 
